Oct 17 (Reuters) - Chinese biotech Hansoh Pharma said on Friday its units have signed a license agreement worth up to $1.45 billion with Roche's subsidiary for an investigational treatment of colorectal cancer and other solid tumors. (Reporting by Sneha Kumar in Bengaluru; Editing by Shailesh Kuber) (The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
